Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease

AIMS: In the COMPASS trial, rivaroxaban 2.5 mg twice daily (bid) plus acetylsalicylic acid (ASA) 100 mg once daily (od) performed better than ASA 100 mg od alone in reducing the rate of cardiovascular disease, stroke, or myocardial infarction (MI) in patients with coronary artery disease (CAD) and p...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cardiovasc Res
Auteurs principaux: Cowie, Martin R, Lamy, André, Levy, Pierre, Mealing, Stuart, Millier, Aurélie, Mernagh, Paul, Cristeau, Olivier, Bowrin, Kevin, Briere, Jean-Baptiste
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Review Series from the Naples 2019 Joint Meeting of the ESC Working Groups on Myocardial Function and Cellular Biology of the Heart
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449563/
https://ncbi.nlm.nih.gov/pubmed/31807773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cvr/cvz278
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires